Clinical Trials Browser

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

NCT01556191 2021-01-08

LADIE

Phase 2 Completed

379 enrolled

Thoracic

Lung Neoplasms

NCT00888511 2020-11-27

TARLAL

Phase 2 Completed

15 enrolled 6 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00033514 2020-10-08

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Phase 1/2 Completed

27 enrolled 12 charts

Breast

Breast Neoplasms

NCT01532089 2020-10-06

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Phase 2 Completed

88 enrolled 15 charts

EGFR Exon 19 Deletion Mutation

NCT00835471 2020-09-29

NVALT10

Phase 2 Completed

195 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00950365 2020-09-16

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

Phase 2 Completed

79 enrolled 13 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00749892 2020-09-10

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Phase 2 Completed

34 enrolled 9 charts

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00769483 2020-09-03

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

Phase 1/2 Completed

81 enrolled 19 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00547105 2020-08-21

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

24 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00087035 2020-08-03

Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

Phase 2 Completed

1 enrolled

Genitourinary

Prostatic Neoplasms

NCT00088946 2020-07-31

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Phase 2 Completed

17 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT00509431 2020-07-31

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

Phase 1 Completed

19 enrolled

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00278148 2020-07-20

Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer

Phase 1/2 Completed

32 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00543504 2020-06-30

Bevacizumab in Multiple Phase I Combinations

Phase 1 Completed

343 enrolled

Advanced Cancer

NCT00313560 2020-06-04

ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

Phase 2 Completed

48 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03403049 2020-04-22

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Phase 1 Completed

14 enrolled

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

Clinical Trials

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

EURTAC

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

BLISS

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Study of Ixazomib and Erlotinib in Solid Tumors

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

NSCLC

Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy

SLAT

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

GEM

ICK

Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

LADIE

TARLAL

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

NVALT10

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer

Bevacizumab in Multiple Phase I Combinations

ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer